ASKA Pharmaceutical Holdings Co., Ltd.

As of March 31, 2026, ASKA Pharmaceutical Holdings Co., Ltd. carries a market capitalization of 67.01B, placing it among publicly traded companies globally. Its enterprise value stands at 73.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, ASKA Pharmaceutical Holdings Co., Ltd. has 28.40M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, ASKA Pharmaceutical Holdings Co., Ltd. maintains a current ratio of 2.76, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, ASKA Pharmaceutical Holdings Co., Ltd.'s stock has declined approximately 7.73% over the past 52 weeks. The 50-day moving average sits at 2,082.72, while the 200-day moving average is 2,343.23.

As of March 31, 2026, ASKA Pharmaceutical Holdings Co., Ltd. holds 11.02B in cash and equivalents against 11.43B in total debt, resulting in a net debt position of 1.31B. Total book value stands at 70.36B, with working capital of 39.13B providing operational flexibility.